Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma
Abstract Despite the favorable effects of immunotherapies in multiple types of cancers, its complete success in CNS malignancies remains challenging. Recently, a successful clinical trial of cytokine-induced killer (CIK) cell immunotherapy in patients with glioblastoma (GBM) has opened a new avenue...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
Nature Portfolio
2025-01-01
|
| Rangatū: | Scientific Reports |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1038/s41598-024-84284-5 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|